Table 1.
Overall | Loss to Follow Up (LTFU) Analysis | ||||
---|---|---|---|---|---|
Statistic (n) | 95% CI | Not LTFU | LTFU | p* | |
Male, % | 53.4 (133) | 44.5 – 62.1 | 49.4 | 59.3 | 0.291† |
NHIF‡ Participant, % | 53.7 (123) | 44.4 – 62.7 | 53.9 | 53.2 | 1.000† |
Age In Months, mean | 41 (133) | 36.7 – 45.3 | 40.0 | 42.4 | 0.601§ |
Months of Symptoms Prior to Diagnosis, mean | 3.1 (66) | 2.2 – 3.9 | 2.97 | 3.2 | 0.800§ |
Days From Presentation To Diagnosis, mean | 15.5 (133) | 9.6 – 21.4 | 20.8 | 7.8 | 0.033§ |
Days From Presentation To First Therapeutic Intervention, mean | 41.2 (118) | 27.6 – 54.8 | 41.4 | 41.0 | 0.973§ |
Days of Follow-Up, mean | 263.3 (133) | 210.4 – 316.2 | 270.4 | 253.0 | 0.750§ |
Number Mobile Numbers, mean | 1.3 (132) | 1.2 – 1.4 | 1.3 | 1.3 | 0.910§ |
Patient HIV** positive, % | 2.4 (42) | 00.0 – 12.6 | 3.7 | 0.0 | 1.000† |
Parent HIV positive, % | 7.4 (27) | 00.9 – 24.2 | 5.9 | 10.0 | 1.000† |
Up Front Resection††, % | 27.6 (127) | 20.0 – 36.1 | 21.6 | 35.9 | 0.107† |
Preoperative Chemotherapy††, % | 74.3 (82) | 63.6 – 83.4 | 64.7 | 90.3 | 0.010† |
Resection††, % | 69.9 (133) | 61.4 – 77.6 | 58.2 | 87.0 | 0.080† |
Postoperative Chemotherapy††, % | 51.8 (83) | 40.6 – 62.9 | 41.5 | 61.9 | 0.002† |
Radiotherapy††, % | 16.8 (131) | 10.8 – 24.3 | 12.7 | 23.1 | 0.153† |
Completed all Therapy, % | 24.8 (133) | 17.7 – 33.0 | 13.9 | 40.7 | 0.001† |
Currently Receving Treatment, % | 18.8 (133) | 12.5 – 26.5 | 31.7 | 0.0 | < 0.001† |
Stage Estimates, % (n = 125) | |||||
I | 3.2 (4) | 2.6 | 4.1 | ||
II | 42.4 (53) | 47.4 | 34.7 | ||
III | 36 (45) | 26.3 | 51.0 | ||
IV | 16.8 (21) | 21.1 | 10.2 | ||
V | 1.6 (2) | 2.6 | 0.0 | 0.034† | |
Laterality % (n = 131) | |||||
Right | 48.1 (63) | 56.4 | 41.5 | ||
Left | 50.4 (66) | 41.0 | 58.5 | ||
Bilateral Synchronous | 1.5 (2) | 2.6 | 0.0 | 0.085† |
p compares NOT lost to follow up to lost to follow up.
Fishers Exact
National Hospital Insurance Fund
T-Test
Human Immunodeficiency Virus
Patient completed the given therapy